TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Implant Radiation Therapy or Surgery in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS~Meeting 1 of the following criteria:~* Prostate cancer or suspected prostate cancer confined to the prostate (Decision-Aid Randomization) Clinical stage T1/T2, Due for prostate biopsy or prostate biopsy performed in the last 6 weeks, PSA \< 15 ng/mL~* Histologically confirmed prostate cancer (Treatment Randomization): Clinical stage T1/T2, Re-biopsy after a period of active surveillance is at the discretion of the treating investigator, Must meet 1 of the following risk criteria (PSA test \< 3 months prior to treatment intervention), Low risk: Gleason score ≤ 6 (no tertiary grade 4 or 5) with a PSA of \< 10 ng/mL, intermediate-risk: Gleason score 3 + 4 (no tertiary grade 5) with a PSA \> 10 ng/mL but ≤ 15 ng/mL, Transrectal ultrasound prostate volume ≤ 50 cc~PATIENT CHARACTERISTICS:~* WHO performance status 0-1~* Life expectancy \> 10 years (Decision-Aid Randomization)~* Satisfactory results from biochemical and hematological profiles that, in the opinion of the investigator, does not preclude patient from the trial~* No unacceptable risk for radical prostatectomy or prostate brachytherapy~* INR \< 1.5~* No severe lower urinary tract symptoms~* No significant obstructive urinary symptoms (i.e., peak urine flow rate \< 10 mL per second, and/or post micturition bladder volume \> 100 mL)~* No other clinical or medical condition that, in the opinion of the investigator, precludes patient from taking part in the trial~* No other active malignancy likely to interfere with subsequent protocol treatment and follow-up~PRIOR CONCURRENT THERAPY:~* No prior pelvic radiotherapy~* No prior abdominoperineal (AP) rectal excision~* No prior standard transurethral resection of prostate~* No prior or concurrent neoadjuvant or adjuvant hormonal treatment, (e.g., LHRH agonists, or anti-androgens or estrogens)~* At least 5 days since prior aspirin or clopidogrel~* No concurrent warfarin

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm Rx1: Radical Prostatectomy (Type: OTHER): Arm Rx1: Radical Prostatectomy
- Arm Rx2: Brachytherapy (Type: OTHER): Arm Rx2: Brachytherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients that have locally advanced or metastatic breast cancer. Lesions should not be amenable to surgery or radiation of curative intent~* Hormone therapy-naive~* Estimated life expectancy of more than 12 weeks~Exclusion Criteria:~* Last dose of prior anti-cancer therapy received within 14 days (or longer if required)~* Any eye injury or corneal surgery within 3 months prior to receiving first dose of study drug.~* Currently receiving (and unwilling to discontinue) oestrogen replacement therapy. (last dose \<7 days prior to randomisation)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD8931 40mg (bd) plus anastrozole 1mg (od)
- 2 (Type: EXPERIMENTAL): AZD8931 20mg (bd) plus anastrozole 1mg (od)
- 3 (Type: PLACEBO_COMPARATOR): Placebo (bd) plus anastrozole 1mg (od)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Serum-derived Bovine Immunoglobulin Effect on Mucositis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed consent obtained and signed~2. Male or female at least 18 years of age~3. Diagnosed with head, neck, or lung cancer and scheduled to undergo combined chemo-radiation therapy~4. Diagnosed with head, neck, or lung cancer with disease stage within the criteria described in 4.0 Staging Criteria~5. Not experiencing diarrhea during the 5 days preceding enrollment, as defined by having less than two unformed bowel movements per day or loose (mushy) or watery stools in the 5 days preceding enrollment.~6. Not currently taking anti-diarrheal medications (prescription or over the counter).~7. Agrees and is able to take the investigational products or placebo starting from the day of enrollment (approximately 7-14 days prior to beginning chemo-radiation therapy) through 6-7 weeks of chemo-radiation therapy (for a total of 8-9 weeks).~Exclusion Criteria:~1. History of uncontrolled diarrhea during screening.~2. History of Irritable Bowel Syndrome with Diarrhea with a normal pattern of more than three bowel movements in a 24 hour period.~3. History of inflammatory bowel disease: ulcerative colitis, Crohn's disease, or microscopic colitis.~4. History of active infectious diarrhea and receiving therapy within 10 days of the first dose of study drug or placebo.~5. Known allergy or intolerance to beef or soy or any ingredient used in the product~6. History of concurrent intensive chemotherapy within 10 days of the first scheduled dose of study drug or placebo.~7. Gastrointestinal surgery or bowel resection that could affect study product absorption (this does not include cholecystectomy or appendectomy).~8. Unable to comply with the protocol requirements.~9. Any condition that in the opinion of the Investigator might interfere with the study objective.~10. Women who are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nutritional therapy (Type: ACTIVE_COMPARATOR): Serum-derived bovine immunoglobulin/protein isolate (SBI) 10.0 grams once daily
- Placebo (Type: PLACEBO_COMPARATOR): Hydrolyzed gelatin 10.0 grams once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acute Labetalol Use in Preeclampsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI ≥ 30~* Age ≥ 18 years~* Gestational age ≥ 24 weeks~* Singleton gestation~* One sustained severe range blood pressure at Albany Medical Center~Exclusion Criteria:~* Known allergic reaction to labetlol~* Persistent mild-moderate asthma (≥ 2 rescue inhaler uses per week in the previous month)~* Obstructive airway disease~* Bradycardia \< 70 beats/min~* Heart block \> 1st degree or history of heart failure

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental labetalol dose (Type: EXPERIMENTAL): Subjects receive 40mg, 60mg 80mg in succession after each severe BP
- Current standard of care (Type: ACTIVE_COMPARATOR): Subjects receive 20mg, 40mg 80mg in succession after each severe BP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ocular Blood Flow in Colorectal Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients (age 18 and over) suffering from mCRC.~* Normal findings in ophthalmic examination (except the investigator finds an abnormality irrelevant for the purpose of the study.)~* Patients, which are scheduled for standard of care treatment with chemotherapy plus bevacizumab~Exclusion Criteria:~* Refusal to give informed consent~* Severe hypertension (RR ≥180/110)~* Epilepsy~* Pregnancy and breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intrathecal Baclofen Therapy and Paroxysmal Dysautonomia in Severe Brain-Injured Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* severe brain injury with coma (Glasgow score \<8)~* Early phase of recovery (spontaneous eye-opening) since at least one month and less than six months~* severe hypertonia of the lower limbs (mean Ashworth score \>= 3) with neurovegetative episodes (at least 10 in 48 hours) and/or decortication after failure of treatment per os (clonidine, beta-blocker, baclofen per os)~* written informed consent (next of kin)~Exclusion Criteria:~* surgical, anesthetic or allergic contraindication to baclofen~* uncontrolled sepsis directly threatening the implanted device~* associated medullary trauma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nebulized and Intravenous Colistin in Ventilator Associated-pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Age older than 18 yr~* Invasive mechanical ventilation for more than 48 h Tracheostomized patients receiving intermittent mechanical ventilation can be included~* VAP caused by Gram-negative MDR bacteria resistant to all β-lactams and fluoroquinolones~Exclusion criteria~* Extrapulmonary Gram-negative MDR infection requiring intravenous colimycin~* VAP associated with bacteremia requiring combined treatment by nebulized and intravenous colimycin~* Hypersensitivity to colistimethate, colistin base, polymyxins and/or their excipients~* Porphyria~* Severe hypoxemia defined as PaO2 / FiO2\< 100; if veno-venous ECMO is initiated, the patient can be included~* Severe brain injury (initial Glasgow coma score \< 8) during the first 7 days before randomization~* Myasthenia~* cystic fibrosis~* Refusal to participate in the study~* Participation in any clinical study of a therapeutic investigational product within 30 days prior to the first day of inclusion~* No affiliation to social health insurance~* Patient under guardianship~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental group (Type: EXPERIMENTAL): Patients receive simultaneously nebulized colimycin every 8 h and intravenous placebo administered once, twice or 3 times per day according to renal function
- Control group (Type: ACTIVE_COMPARATOR): Patients receive simultaneously intravenous colimycin administered once, twice or 3 times per day according to function renal and nebulized placebo every 8 h

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Remote Electrical Neuromodulation for Acute Procedural Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the criteria for 1.3 chronic migraine based on ICHD3 criteria.~* Currently receiving onabotulinumtoxinA per PREEMPT protocol for the treatment of chronic migraine.~* Have remained stable on their current headache medication for a minimum of 8 weeks.~* Patient is willing and able to comply with the protocol to the satisfaction of the investigator.~* Patient has the capacity to provide written, informed consent for themselves.~Exclusion Criteria:~* Participants with an active implanted electrical and/or neurostimulator device (e.g., cardiac pacemaker, cochlear implant).~* Participants with congestive heart failure (CHF), severe cardiac or cerebrovascular disease.~* Participants with uncontrolled epilepsy.~* Change in migraine preventive medications (type or dose) in the last two months prior to recruitment and/or during the study.~* Pregnant, trying to get pregnant or breastfeeding female participants.~* Subjects participating in any other interventional clinical study.~* Participants with other significant pain, medical or psychological problems that in the opinion of the investigator may confound the study assessments.~* Participants who have previous experience with the device.~* Patients with cranial deformities, prior cranial surgeries with violation of the calvarium, or shunt placement.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Electrical Neuromodulation, Then Sham (Type: EXPERIMENTAL): Subjects will first have the Nerivio ® applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 12. Subjects will then have the sham device applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 24.
- Sham, Then Electrical Neuromodulation (Type: EXPERIMENTAL): Subjects will first have the sham device applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 12. Subjects will then have the Nerivio ® applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vascular Dysfunction in Hypertensive Postmenopausal Women

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Women.~* \> 1year post menopausal.~* Age range 50-70 years~* Resting ECG in normal limits~* Standard blood chemistry within normal limits~* Systolic blood pressure: \<130mm Hg for normotensives; \>130mm Hg for hypertensives.~* Diastolic blood pressure: \< 80mm Hg for normotensives; \> 80mm Hg for hypertensives.~Exclusion Criteria:~* History of cardiovascular disease~* Blood clots or stroke~* Cancer~* Diabetes~* Kidney or Liver disease~* Obesity (BMI\>35kg/m2)~* Pregnant/Breast feeding~* Current use of hormone therapy~* Current use of tobacco products~* High cholesterol~* Current use of anti-hypertensive meds

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Normotensive (Type: OTHER): Normotensive PMW will complete an experimental visit to assess vascular function. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visit to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
- Hypertensives (Type: EXPERIMENTAL): Hypertensive women will be tested at baseline and then administered Losartan 50 mg once a day at night for 14 days. Vascular function is measured at baseline and again after 2 weeks of losartan. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visits to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologic proof of papillary-serous ovarian cancer or 1ary peritoneal carcinomatosis.~2. Histological grade III.~3. Original disease in stage III.~4. ECOG performance status: 0-2.~5. Age: 20-80 years.~6. Previous chemotherapy with paclitaxel and carboplatin (only).~7. Previous cyto-reductive surgery.~8. Clinical Complete Response (both physically and by imaging).~9. CA 125 should be either normalized (in at least 50 patients) or while still in decreasing values at monthly measurements.~10. CBC at normal values or with any toxicity at a grade limited to I by NCIC-CTC.~11. Liver and renal functions \< 1.5 upper normal limits (UNL) by SMA.~12. The patient's signature on the informed consent.~Exclusion Criteria:~1. Mucinous type ovarian carcinoma.~2. Histological Grade I-II.~3. Current continuous treatment by steroids or by NSAIDs, or by anti-coagulants for non protocol reasons.~4. Previous history of active peptic ulcer.~5. Current participation in any other treatment study.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Metronomic Chemoterapy (Type: EXPERIMENTAL): Maintenance Treatment for Ovary Carcinoma by Metronomic Chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Long-Pulsed Dye Laser and Intense Pulsed Light for Skin Rejuvenation.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Mild to moderate bilateral facial photodamage~* Symmetry in the facial area of wrinkles, skin texture, pigmentary changes and telangiectasia~* Fitzpatrick's skin type of Type I, II, or III, without significant tan~* Age \> 40 years~* Able to read and comprehend Danish~* Informed consent agreement signed by the subject~* Willingness to follow the treatment schedule and posttreatment follow-up evaluations~* Willingness to allow photographs of the treated area to be taken for evaluation of efficacy.~Exclusion Criteria:~* Scarring or infection of the area to be treated~* Known photosensitivity~* Presence of a suntan in the area to be treated~* Subjects taken medication known to induce photosensitivity in the previous three months~* Known anticoagulation or thromboembolic conditions~* Subjects taking anticoagulation medication~* Subjects taking Accutane within the past 6 months~* Subjects treated with aspirins or anti-inflammatory drugs~* Subjects who are immunocompromised or have a medical history that is inappropriate for the study per the investigator's clinical judgment.~* Dermabrasion, chemical peel, laser or IPL treatment, or collagen injection therapy in the facial area in the past 12 months.~* Previous formation of hypertrophic scars or keloids~* Subjects who are pregnant or lactating~* Asymmetry in the facial area of wrinkles, skin texture, pigmentary changes and telangiectasia

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Predictive Factors Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Acromegaly.~* Males and females aged 18 years and older.~* Signed informed consent (patient must give consent to the collection of retrospective data).~* Patients who have had surgery may enter the study 3 months post-surgery and evaluated for the duration of the study.~* With the intention to be treated with ATG (decision to prescribe ATG made prior to inclusion into the study) or already being treated with ATG.~* If already being treated with ATG:~Previous ATG treatment maximum of 3 months. AND Minimum data available (demographic data, disease history including previous treatments, GH, IGF-1 levels at baseline and under treatment as applicable).~* Not receiving Dopamine Agonists or other medical therapy (Pegvisomant, or other somatostatin analogues) for the treatment or symptom control of acromegaly.~Exclusion Criteria:~* The subject has had radiotherapy in the last 5 years.~* The subject has had surgery in the last 3 months.~* The subject has already been included in this study.~* Participation in an interventional trial, or receiving experimental drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acromegalic patients (Type: None): Acromegalic subjects treated with Somatuline Autogel® (Lanreotide)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues